Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-SARS-2-ST vaccine in healthy and mRNA-vaccinated adults
NCT04895449Phase 1Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of MVA-SARS-2-ST in coronavirus disease 2019 (COVID-19), sponsored by University Medical Center Hamburg-Eppendorf. Started Jul 2021; status: completed.
02
Drugs
MVA-SARS-2-ST
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04895449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895449.